Bankers and consultants have long been urging the virtues of consolidation onto a financially strapped biotech industry. But few companies on either side of the Atlantic have been listening.
Tracking intra-European dealmaking by type of acquirer and target, Windhover's Strategic Transactions Database shows that overall dealmaking has declined, with...
Welcome to In Vivo
Create an account to read this article
Already a subscriber?